종양학용 인공지능 시장 : 암 유형별, 최종사용자 유형별, 주요 지역별 - 업계 동향과 세계 예측(-2035년)

Artificial Intelligence in Oncology Market by Type of Cancer, Type of End-Users, Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,674,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,734,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,741,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,033,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

종양학에서 세계의 인공지능(AI) 시장 규모는 2035년까지의 예측 기간 중 21.4%의 CAGR로 확대하며, 현재 11억 달러에서 2035년까지 91억 달러로 성장할 것으로 예측됩니다.

지난 10년간 AI의 인기는 꾸준히 증가하고 있습니다. 종양학 분야를 포함하여 의료 헬스케어 분야 전반에 상당한 영향을 미치고 있습니다. 이는 진단과 치료를 위한 AI 기반 기술의 급격한 증가에 기인합니다. 기술 인프라와 획기적인 연구 성과를 고려할 때, AI는 의료의 복잡성을 극복하고 제약/바이오/의료기기 분야에서 미충족 수요를 충족시킬 수 있을 것으로 예상되며, AI는 종양 영상 진단 및 치료 효과 평가를 개선하고, 임상 결과를 예측하고, 의약품 개발 및 AI는 기존 문제를 극복하고 빅데이터의 힘을 활용하여 암 치료를 더욱 개선함으로써 암 치료 분야에 혁명을 일으킬 수 있는 잠재력을 가지고 있으며, AI는 이미 종양학 임상 현장에서 활용되고 있지만, AI가 그 잠재력을 최대한 발휘하기 위해서는 그 잠재력을 최대한 발휘할 수 있도록 하기 위해서는 지속적 이고 더 많은 노력이 필요합니다. 산업계와 비산업계 모두 종양학 분야에서 AI 기반 솔루션을 사용하기 위한 지속적인 노력에 힘입어 종양학 시장은 향후 지속가능한 성장을 보일 것으로 예상됩니다.

현재 종양학 분야 AI 기반 소프트웨어 솔루션 개발에는 70개 이상의 기업이 참여하고 있습니다.

50% 이상의 진입기업이 병원에서 진단 목적으로 머신러닝을 활용한 솔루션을 사용하고 있습니다. 경쟁 우위를 확보하기 위해 업계 이해관계자들은 기존 역량을 적극적으로 업그레이드하고 AI에 초점을 맞춘 서비스 포트폴리오를 강화하고 있습니다. 이 시장에 대한 관심이 높아지고 있는 것은 최근 파트너십 활동이 활발해지고 있는 것을 보면 알 수 있습니다.

이 시장은 향후 10년간 21% 이상의 건강한 성장이 예상되며, 그 기회는 다양한 적응증, 분자 유형, 다양한 지역으로 분산될 가능성이 높습니다.

세계의 종양학용 인공지능 시장에 대해 조사했으며, 시장의 개요와 암 유형별, 최종사용자 유형별, 주요 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 서문

제2장 개요

제3장 서론

제4장 시장 구도

제5장 기업 개요

• 챕터 개요
• Roche Diagnostics
• IBM Watson Health
• CancerCenter.AI
• GE Healthcare
• Concert AI
• Path AI
• Berg
• Median Technologies
• iCAD
• JLK Inspection

제6장 기업 경쟁력 분석

제7장 특허 분석

제8장 파트너십과 협업

제9장 자금조달과 투자 분석

제10장 블루 오션 전략 : 경쟁 치열한 시장에 참여하는 스타트업을 위한 전략 가이드

제11장 시장 규모의 평가와 기회 분석

• 챕터 개요
• 주요 전제와 조사 방법
• 종양학에서 세계의 인공지능 시장, 2035년까지
• 종양학 시장에서 인공지능 : 2035년까지 암 유형별 분석
• 종양학 시장에서 인공지능 : 2035년까지 최종사용자 유형별 분석
• 종양학 시장에서 인공지능 : 2035년까지의 주요 지역별 분석

제12장 결론

제13장 이그제큐티브 인사이트

• 챕터 개요
• Enlitic
• Nucleai
• Mirada Medical
• CancerCenter.AI
• Visiopharm

제14장 부록 1 : 표 형식 데이터

제15장 부록 2 : 기업·단체 리스트

KSA

영문 목차

영문목차

ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: OVERVIEW

As per Roots Analysis, the global artificial intelligence (AI) in oncology market is estimated to grow from USD 1.1 billion in the current year to USD 9.1 billion by 2035, at a CAGR of 21.4% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Cancer

• Solid malignancies
• Breast cancer
• Lung cancer
• Prostate cancer
• Colorectal cancer
• Brain tumor
• Others

Type of End Users

• Hospitals
• Pharmaceutical companies
• Research Institutes
• Others

Type of End Users

• North America
• Europe
• Asia-Pacific
• Rest of the World

ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: GROWTH AND TRENDS

In the last decade, the popularity of AI has grown steadily. It has made a considerable impact on the overall medical healthcare sector, including in the field of oncology. This can be attributed to the surge in AI-based technologies for diagnosis and treatment. Given the breakthroughs in technological infrastructure and groundbreaking research, it is anticipated that AI is likely to overcome the complexities of medicine and has the potential to address the unmet needs within the pharmaceutical / biotech / medical devices domain. AI has demonstrated potential in improving tumor imaging diagnosis and therapy response evaluation, anticipating clinical outcomes, and accelerating drug development and translational oncology. AI has the potential to revolutionize the oncology sector by overcoming existing challenges and leveraging the power of big data to improve the cancer treatment further. Although AI is already being used in oncology clinical practice, ongoing and increased efforts are required to allow AI to reach its full potential. Driven by the continuous efforts of both industry and non-industry players to use AI based solutions in the oncology sector, the market is expected to witness sustainable growth in the foreseen future.

ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: KEY INSIGHTS

The report delves into the current state of artificial intelligence in oncology market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• The current market landscape features the presence of over 70 players engaged in the development of AI-based software solutions for the oncology sector.

• Over 50% of the players use their machine learning powered solutions for diagnostic purposes in hospitals; geographically, the software providers are well distributed.
• In pursuit of gaining a competitive edge, industry stakeholders are actively upgrading their existing capabilities and enhancing their AI focused service portfolios.
• The growing interest in this market is prevalent from the recent rise in partnership activity; ~50% of the deals were inked to enable utilization and integration of proprietary AI-based technology solutions.
• Foreseeing lucrative returns, many public and private investors have made investments worth ~USD 6 billion; 70% of the funding initiatives were led by venture capitalists.
• Over 2,770 patents have been granted / filed by academic and industry stakeholders in the last five years, exclusively for the development of AI-based software solutions for oncology.
• The market is expected to witness a healthy growth of over 21% in the coming decade; the opportunity is likely to be well distributed across various target indications, types of molecules and different regions.

ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: KEY SEGMENTS

Solid Malignancies Segment is Likely to Dominate AI in Oncology Market During the Forecast Period

Based on the type of cancer, the market is segmented into solid malignancies, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain tumor, and others based on the type of cancer. At present, the solid malignancies segment holds the maximum share of the AI in oncology market. This trend is likely to remain the same in the coming decade.

Currently, Hospitals Segment Occupies the Largest Share of the AI in Oncology Market

Based on the type of end-user, the market is segmented into hospitals, pharmaceutical companies, research institutes and others. At present, the hospital segment holds the maximum share of the AI in oncology market. This trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority of the current AI in oncology market is captured by North America. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the Artificial Intelligence in Oncology Market

• Berg
• CancerCenter.AI
• Concert AI
• GE Healthcare
• IBM Watson Health
• iCAD
• JLK Inspection
• Median Technologies
• Path AI
• Roche Diagnostics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer, CancerCenter.AI
• Chief Executive Officer, Nucleai
• Chief Executive Officer, Visiopharm
• Vice President, Marketing and Communications, Enlitic

ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the AI in oncology market, focusing on key market segments, including [A] type of cancer, [B] type of end-user and [C] key geographical regions.
• Market Landscape: A comprehensive evaluation of companies engaged in the development of AI in oncology-based software solutions, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] type of service(s) offered, [E] type of AI technology used, [F] type of platform and [G] type of end-user.
• Company Profiles: In-depth profiles of key industry players offering AI in oncology-based software solutions, focusing on [A] company overviews, [B] proprietary technology platform(s), [C] AI focused service portfolio, [D] recent developments and [E] an informed future outlook.
• Company Competitiveness Analysis: A comprehensive competitive analysis of companies engaged in the development of AI in oncology-based software solutions, examining factors, such as [A] supplier strength [B] portfolio diversity and [C] portfolio strength.
• Patent Analysis: Detailed analysis of various patents filed / granted related to AI in oncology-based software solutions based on [A] type of patent, [B] publication year, [C] geographical location / patent jurisdiction, [D] legal status, [E] CPC symbols, [F] type of industry, [G] type of applicant and [H] leading players (in terms of number of patents filed / granted). It also includes a detailed patent valuation analysis.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2017, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] most active players (analysis by parent company and analysis by partner company), [D] type of partner, [E] type of cancer and [F] region.
• Funding and Investment Analysis: A detailed evaluation of the investments made in the ADC domain, encompassing seed financing, venture capital financing, debt financing, grants, IPOs and other offerings based on several parameters, such as [A] year of funding, [B] type of funding, [C] leading players (in terms of amount invested) and [D] key investors.
• Blue Ocean Strategy: A detailed analysis of the current and future market based on blue ocean strategy, covering a strategic plan / guide for emerging players in AI in oncology market to help unlock an uncontested market, featuring thirteen strategic tools that can help software developers to shift towards a blue ocean strategic market.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Overview
• 1.2. Scope of the Report
• 1.3. Market Segmentation
• 1.4. Research Methodology
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

• 2.1. Chapter Overview

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Overview of Artificial Intelligence
• 3.3. Types Of Artificial Intelligence
• 3.4. AI in Healthcare
• 3.5. Key Challenges Associated with Use of AI in Healthcare Sector
• 3.6. Future Perspectives

4. MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. AI in Oncology: Market Landscape of Software Providers
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters (Region-wise)
  • 4.2.4. Analysis by Location of Headquarters (Country-wise)
  • 4.2.5. Analysis by Type of End-User
  • 4.2.6. Analysis by Year of Establishment, Company size and Location of Headquarters
• 4.3. AI in Oncology: Market Landscape of Software Solutions
  • 4.3.1. Analysis by Type of Service(s) Offered
  • 4.3.2. Analysis by Type of AI Technology Used
  • 4.3.3. Analysis by Type of Platform
  • 4.3.4. Analysis by Type of Service(s) Offered and Type of End-User
  • 4.3.5. Analysis by Type of Platform and Type of AI Technology Used
  • 4.3.6. Analysis by Type of Service(s) Offered, Location of Headquarters and Type of AI Technology Used

5. COMPANY PROFILES

• 5.1. Chapter Overview
• 5.2. Roche Diagnostics
  • 5.2.1. Company Overview
  • 5.2.2. Financial Information
  • 5.2.3. Service Portfolio
  • 5.2.4. Recent Developments and Future Outlook
• 5.3. IBM Watson Health
  • 5.3.1. Company Overview
  • 5.3.2. Financial Information
  • 5.3.3. Service Portfolio
  • 5.3.4. Recent Developments and Future Outlook
• 5.4. CancerCenter.AI
  • 5.4.1. Company Overview
  • 5.4.2. Service Portfolio
  • 5.4.3. Recent Development and Future Outlooks
• 5.5. GE Healthcare
  • 5.5.1. Company Overview
  • 5.5.2. Financial Information
  • 5.5.3. Service Portfolio
  • 5.5.4. Recent Development and Future Outlook
• 5.6. Concert AI
  • 5.6.1. Company Overview
  • 5.6.2. Service Portfolio
  • 5.6.3. Recent Developments and Future Outlook
• 5.7. Path AI
  • 5.7.1. Company Overview
  • 5.7.2. Service portfolio
  • 5.7.3. Recent Development and Future Outlook
• 5.8. Berg
  • 5.8.1. Company Overview
  • 5.8.2. Service Portfolio
  • 5.8.3. Recent Development and Future Outlook
• 5.9. Median Technologies
  • 5.9.1. Company Overview
  • 5.9.2. Financial Information
  • 5.9.3. Service Portfolio
  • 5.9.4. Recent Development and Future Outlook
• 5.10. iCAD
  • 5.10.1. Company Overview
  • 5.10.2. Financial Information
  • 5.10.3. Service Portfolio
  • 5.10.4. Recent Developments and Future Outlook
• 5.11. JLK Inspection
  • 5.11.1. Company Overview
  • 5.11.2. Service Portfolio
  • 5.11.3. Recent Development and Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS

• 6.1. Chapter Overview
• 6.2. Assumptions / Key Parameters
• 6.3. Methodology
  • 6.3.1. Company Competitiveness: Small Companies in North America
  • 6.3.2. Company Competitiveness: Small Companies in Europe
  • 6.3.3. Company Competitiveness: Small Companies in Asia Pacific
  • 6.3.4. Company Competitiveness: Mid-sized companies in North America
  • 6.3.5. Company Competitiveness: Mid-sized companies in Europe
  • 6.3.6. Company Competitiveness: Mid-sized companies in Asia Pacific
  • 6.3.7. Company Competitiveness: Large companies in North America and Europe

7. PATENT ANALYSIS

• 7.1. Chapter Overview
• 7.2. Scope and Methodology
• 7.3. AI in Oncology: Patent Analysis
  • 7.3.1. Analysis by Type of Patent
  • 7.3.2. Analysis by Patent Publication Year
  • 7.3.3. Analysis by Year-wise Trend of Filed Patent Applications and Granted Patents
  • 7.3.4. Analysis by Jurisdiction
  • 7.3.5. Analysis by Type of Industry
  • 7.3.6. Analysis by Patent Age
  • 7.3.7. Analysis by Legal Status
  • 7.3.8. Analysis by CPC Symbols
  • 7.3.9. Most Active Players: Analysis by Number of Patents
  • 7.3.10. Analysis by Key Inventors
• 7.4. AI in Oncology: Patent Benchmarking Analysis
  • 7.4.1. Analysis by Patent Characteristics
  • 7.4.2. AI in Oncology: Patent Valuation Analysis

8. PARTNERSHIPS AND COLLABORATIONS

• 8.1. Chapter Overview
• 8.2. Partnership Models
• 8.3. AI in Oncology: Recent Partnerships and Collaborations
  • 8.3.1. Analysis by Year of Partnership
  • 8.3.2. Analysis by Type of Partnership
  • 8.3.3. Analysis by Year and Type of Partnership
  • 8.3.4. Analysis by Company Size and Type of Partnership
  • 8.3.5. Most Active Partners: Analysis by Number of Partnerships
  • 8.3.6. Most Active Players: Analysis by Type of Partnership
  • 8.3.7. Analysis by Type of Cancer
  • 8.3.8. Analysis by Type of Partner
  • 8.3.9. Analysis by Year and Type of Partner
  • 8.3.10. Intercontinental and Intracontinental Agreements
  • 8.3.11. Local and International Agreements
  • 8.3.12. Country-Wise Distribution
  • 8.3.13. Analysis by Region

9. FUNDING AND INVESTMENT ANALYSIS

• 9.1. Chapter Overview
• 9.2. Types of Funding Models
• 9.3. AI in Oncology: List of Funding and Investment Analysis
  • 9.3.1. Analysis by Year and Number of Funding Instances
  • 9.3.2. Analysis by Year and Amount Invested
  • 9.3.3 Analysis by Type of Funding and Number of Instances
  • 9.3.4. Analysis by Year, Type of Funding and Amount Invested
  • 9.3.5. Analysis by Type of Funding and Amount Invested
  • 9.3.6. Analysis by Area of Application
  • 9.3.7. Analysis by Focus Area
  • 9.3.8. Analysis by Type of Cancer Indication
  • 9.3.9. Analysis by Geography
  • 9.3.10. Most Active Players by Number of Instances
  • 9.3.11. Most Active Players by Amount Invested
  • 9.3.12. Analysis by Type of Investors
  • 9.3.13. Analysis by Lead Investors
• 9.4. Summary of Investments
• 9.5. Concluding Remarks

10. BLUE OCEAN STRATEGY: A STRATEGIC GUIDE FOR START-UPS TO ENTER INTO HIGHLY COMPETITIVE MARKET

• 10.1. Chapter Overview
• 10.2. Overview of Blue Ocean Strategy
  • 10.2.1. Red Ocean
  • 10.2.2. Blue Ocean
  • 10.2.3. Difference between Red Ocean Strategy and Blue Ocean Strategy
  • 10.2.4. AI in Oncology: Blue Ocean Strategy and Shift Tools
    • 10.2.4.1. Value Innovation
    • 10.2.4.2. Strategy Canvas
    • 10.2.4.3. Four Action Framework
    • 10.2.4.4. Eliminate-Raise-Reduce-Create (ERRC) Grid
    • 10.2.4.5. Six Path Framework
    • 10.2.4.6. Pioneer-Migrator-Settler (PMS) Map
    • 10.2.4.7. Three Tiers of Noncustomers
    • 10.2.4.8. Sequence of Blue Ocean Strategy
    • 10.2.4.9. Buyer Utility Map
    • 10.2.4.10. The Price Corridor of the Mass
    • 10.2.4.11. Four Hurdles to Strategy Execution
    • 10.2.4.12. Tipping Point Leadership
    • 10.2.4.13. Fair Process
• 10.3. Conclusion

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 11.1. Chapter Overview
• 11.2. Key Assumptions and Methodology
• 11.3. Global Artificial Intelligence in Oncology Market, till 2035
• 11.4. Artificial Intelligence in Oncology Market: Analysis by Type of Cancer, till 2035
  • 11.4.1. Artificial Intelligence in Oncology Market for Breast Cancer, till 2035
  • 11.4.2. Artificial Intelligence in Oncology Market for Lung Cancer, till 2035
  • 11.4.3. Artificial Intelligence in Oncology Market for Prostate Cancer, till 2035
  • 11.4.4. Artificial Intelligence in Oncology Market for Colorectal Cancer, till 2035
  • 11.4.5. Artificial Intelligence in Oncology Market for Brain Tumor, till 2035
  • 11.4.6. Artificial Intelligence in Oncology Market for Solid Malignancies, till 2035
  • 11.4.7. Artificial Intelligence in Oncology Market for Other Cancers, till 2035
• 11.5. Artificial Intelligence in Oncology Market: Analysis by Type of End-User, till 2035
  • 11.5.1. Artificial Intelligence in Oncology Market for Hospitals, till 2035
  • 11.5.2. Artificial Intelligence in Oncology Market for Pharmaceutical Companies, till 2035
  • 11.5.3. Artificial Intelligence in Oncology Market for Research Institutes, till 2035
  • 11.5.4. Artificial Intelligence in Oncology Market for Other End-Users, till 2035
• 11.6. Artificial Intelligence in Oncology Market: Analysis by Key Geographical Regions, till 2035
  • 11.6.1. Artificial Intelligence in Oncology Market in North America, till 2035
  • 11.6.2. Artificial Intelligence in Oncology Market in Europe, till 2035
  • 11.6.3. Artificial Intelligence in Oncology Market in Asia Pacific, till 2035
  • 11.6.4. Artificial Intelligence in Oncology Market in Rest of the World, till 2035

12. CONCLUSION

• 12.1. Chapter Overview

13. EXECUTIVE INSIGHTS

• 13.1. Chapter Overview
• 13.2. Enlitic
  • 13.2.1. Company Snapshot
  • 13.2.2. Interview Transcript: Vice President, Marketing and Communications
• 13.3. Nucleai
  • 13.3.1. Company Snapshot
  • 13.3.2. Interview Transcript: Chief Executive Officer
• 13.4. Mirada Medical
  • 13.4.1. Company Snapshot
  • 13.4.2. Interview Transcript: Chief Executive Officer
• 13.5. CancerCenter.AI
  • 13.5.1. Company Snapshot
  • 13.5.2. Interview Transcript: Chief Executive Officer
• 13.6. Visiopharm
  • 13.6.1. Company Snapshot
  • 13.6.2. Interview Transcript: Chief Executive Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료